Research Highlights: SRT1720 Experimental Drug Inhibits Bladder Cancer Development

Advertisements
Advertisements

Related Posts:


SRT1720 Experimental Drug Inhibits Bladder Cancer Development

September 4, 2021

  • Bladder cancer is the sixth most common malignancy in the United States.[2]
  • The most common clinical presentation of bladder cancer is the presence of blood in the urine.[2]
  • Smoking is a major risk factor for bladder cancer.[3]
  • New therapeutic targets and drugs for bladder cancer are needed in clinical settings.
  • Most of the past research relied on limited bladder cancer cell lines.
  • Tumor heterogeneity and pathology of this disease are not well represented with limited bladder cancer cell lines.
  • An organoid is a small and simplified version of an organ produced in three dimensions that shows realistic micro-anatomy.[4]
  • Cancer organoids can repeat pathological and molecular properties of bladder cancer.
  • Researchers evaluate the first bladder cancer organoid-based molecule, SRT1720, for epigenetic drugs.
  • SRT1720 is a drug that was studied by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1.[1]
  • SIRT1 is a gene involved in the deacetylation of histones and a number of nonhistone substrates that can affect multiple signaling pathways.[5]
  • Many studies showed that SIRT1 could act as either a tumor suppressor or tumor promoter depending on its targets in specific cancers.[5]
  • Researchers found that SRT1720 significantly inhibits the development of both mouse and human bladder cancer organoids.
  • SRT1720 also prevents the development of bladder cancer in mouse and human patient-derived xenograft bladder cancer.
  • When SIRT1 is mutated, the growth of cancer organoids is increased and their sensitivity to SRT1720 is decreased.
  • The finding proves that SRT1720 targets the SIRT1 in bladder cancer.
  • Researchers also found that SRT1720 treatment can inhibit the development of hypoxia.
  • Additionally, the SIRT1-repressed gene signature is linked with the hypoxia target gene signature and poor prognosis in human bladder cancer.
  • The study demonstrated the power of drug discovery using cancer organoids and identifies SRT1720 as a new therapy for bladder cancer.

Related Video

Sources:

Tan, P., Wang, M., Zhong, A. et al. SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis. Oncogene (2021). https://doi.org/10.1038/s41388-021-01999-9

[1] https://en.wikipedia.org/wiki/SRT-1720

[2] https://pubmed.ncbi.nlm.nih.gov/29094888

[3] https://www.cancer.gov/types/bladder

[4] https://en.wikipedia.org/wiki/Organoid

[5] https://pubmed.ncbi.nlm.nih.gov/24020000

Advertisements
Advertisements

Related Research

Research Article: Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis

Date Published: October 18, 2013 Publisher: Public Library of Science Author(s): Chanhoo Jeon, Myong Kim, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku, Antonia Vlahou. http://doi.org/10.1371/journal.pone.0076719 Abstract: The objective of the present study was to conduct a systematic review and meta-analysis of the published literature investigating the surviving expression and its effects on bladder cancer prognosis. … Continue reading

Research Article: Progress in Personalizing Chemotherapy for Bladder Cancer

Date Published: February 13, 2012 Publisher: Hindawi Publishing Corporation Author(s): James S. Chang, Primo N. Lara, Chong-Xian Pan. http://doi.org/10.1155/2012/364919 Abstract: Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However, there are currently no methods to predict chemotherapy response in this disease setting. A better understanding of the biology … Continue reading